Retatrutide, also known by the development code LY3437943, is a synthetic 39-residue peptide engineered with non-coded amino acids and a C20 fatty diacid side chain. It remains an investigational compound and is not approved for any human or veterinary use. This product is supplied in a sealed vial as a lyophilized powder for use by qualified researchers in controlled laboratory settings.
Research background
Published pharmacology describes retatrutide as a single molecule with agonist activity at three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). In vitro, it is used as a tool compound in receptor binding and signaling studies. These references are provided as scientific background only and do not describe any intended use of this product.
Lot verification
Each vial of Retatrutide carries a lot number linked to its own LIV MORE test results. See the Specification tab for compound data and the Test Results page for batch results.
Research use only. This product is intended solely for in vitro laboratory research by qualified professionals. It is not for human or veterinary use and is not a drug, food, dietary supplement or cosmetic. It has not been approved by the U.S. Food and Drug Administration and is not intended to diagnose, treat, cure, mitigate or prevent any disease.

